These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34859693)

  • 21. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prehospital continuous positive airway pressure for acute respiratory failure: the ACUTE feasibility RCT.
    Fuller GW; Keating S; Goodacre S; Herbert E; Perkins GD; Rosser A; Gunson I; Miller J; Ward M; Bradburn M; Thokala P; Harris T; Marsh MM; Scott AJ; Cooper C
    Health Technol Assess; 2021 Feb; 25(7):1-92. PubMed ID: 33538686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.
    Soares MO; Welton NJ; Harrison DA; Peura P; Shankar- Hari M; Harvey SE; Madan JJ; Ades AE; Palmer SJ; Rowan KM
    Health Technol Assess; 2012; 16(7):1-186. PubMed ID: 22361003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the efficiency of adaptive sample size design.
    Cui L; Zhang L
    Stat Med; 2019 Mar; 38(6):933-944. PubMed ID: 30450621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient adaptive designs with mid-course sample size adjustment in clinical trials.
    Bartroff J; Lai TL
    Stat Med; 2008 May; 27(10):1593-611. PubMed ID: 18275090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
    Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
    BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
    Everest L; Chen BE; Hay AE; Cheung MC; Chan KKW
    BMC Med Res Methodol; 2023 Aug; 23(1):179. PubMed ID: 37537545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis.
    Flight L; Arshad F; Barnsley R; Patel K; Julious S; Brennan A; Todd S
    Value Health; 2019 Apr; 22(4):391-398. PubMed ID: 30975389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Covariate adjustment in Bayesian adaptive randomized controlled trials.
    Willard J; Golchi S; Moodie EE
    Stat Methods Med Res; 2024 Mar; 33(3):480-497. PubMed ID: 38327082
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.